Vertex Pharmaceuticals Incorporated · VRTX · FY2026 Q1 · Calendar Q2 2026

Vertex Q1: Revenue Up 8%, Renal Pipeline Advances, Guidance Reaffirmed

Vertex is executing a deliberate shift from a single-franchise CF company to a multi-pillar biotech. Q1 2026 revenue of $2.99 billion (up 8% YoY) was driven by both the core CF franchise and new non-CF launches KASJEVY and GERNAVICS, which together contributed roughly a quarter of growth. The interim Phase III IgAN data for Povi — 52% proteinuria reduction with a strong safety profile — and the record 27-day BLA submission position the renal franchise as Vertex's emerging fourth commercial pillar. Label expansions for AlifTrack and TRIKAFTA now cover approximately 95% of the CF population, extending the durability of the core franchise. Management reaffirmed full-year guidance of $12.95–$13.10 billion, signaling confidence in the trajectory despite the VX-522 mRNA CF program discontinuation. The stock traded with a -2.1% abnormal return in the reaction window on 1.8x baseline volume…

Reported After market closeNASDAQHealthcare $121.57B market cap
100quality score

Company context

Snapshot as of publication

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline.…

Earnings scorecard

Reported versus consensus
Reported EPS $4.47 Consensus $4
EPS surprise +5.4% Reported versus consensus
Reported revenue $2.99B Consensus $2.99B
Revenue surprise -0.2% Reported versus consensus

Market reaction

event-close to next-session close
Stock move -1.3% Event window
SPY move +0.8% Same window
Abnormal move -2.1% Stock minus SPY
Volume 1.8× Versus trailing sessions
Subsequent drift +0.9% Up to 20 sessions
VRTXSPY benchmark

Follow VRTX with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Transcript intelligence

What changed

Q1 2026 revenue rose 8% year-over-year to $2.99 billion, essentially in line with consensus. EPS of $4.47 beat estimates of $4.24 by 5.4%. New launches KASJEVY and GERNAVICS together accounted for approximately 25% of quarterly growth. Povi's interim Phase III data in IgA nephropathy demonstrated a 52% reduction in proteinuria with a strong safety profile, and Vertex submitted a BLA for the indication in 27 days — the fastest submission in company history. KASJEVY secured its first reimbursement agreement in Germany. The VX-522 mRNA CF program was discontinued due to lung inflammation caused by the lipid nanoparticle delivery system. Label expansions for AlifTrack and TRIKAFTA now cover roughly 95% of CF genotypes, adding approximately 800 newly eligible U.S. patients.

Guidance delta

Full-year 2026 revenue guidance of $12.95–$13.10 billion (8–9% growth) was reaffirmed, as was the expectation for non-CF revenue exceeding $500 million and non-GAAP operating expenses of $5.65–$5.75 billion. Guidance sentiment was maintained with no upward or downward revision.

Key takeaways

  • Q1 revenue of $2.99B rose 8% YoY, with new launches KASJEVY and GERNAVICS driving roughly 25% of growth
  • Povi interim Phase III IgAN data showed 52% proteinuria reduction with strong safety, supporting near-term launch
  • CF label expansions for AlifTrack and TRIKAFTA now cover ~95% of eligible patients, adding ~800 newly eligible U.S. patients
  • BLA for Povi in IgAN submitted in 27 days, the fastest in Vertex history
  • VX-522 mRNA CF program discontinued due to delivery-related lung inflammation
  • KASJEVY secured its first reimbursement agreement in Germany

Management priorities

  • Submit AlifTrack for approval in 2–5-year-old patients and TRIKAFTA for 1–2-year-old patients
  • Complete Phase III interim analysis presentation for Povi IgAN and prepare for product launch pending approval
  • Advance Povi Phase III in primary membranous nephropathy and Phase II in myasthenia gravis
  • Deliver Phase III results for enaxaplin AMPLITUDE in early 2027 and analyze AMPLIFIED data later this year
  • Resume dosing in the zamylosel trial after manufacturing analysis and provide updated timelines
  • Continue development of next-gen CFTR programs (VX-828, VX-581, VX-2272) through Phase I/II studies in H2 2026

Related earnings events

Healthcare
TMO · FY2026 Q2 · Calendar Q3 2026TMO Q2 2026: Revenue Up 10%, EPS Up 13% as Guidance Rises Again

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-07-29T00:14:37.730999+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-29T00:14:37.728258+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.